As Marty Makary and Jay Bhattacharya sail through the Senate health committee vote, Weldon's confirmation hearing is canceled ...

The move by Acelyrin’s board comes as the venture capital firm has taken larger and larger stakes in the company in an ...

While Houston isn’t yet on the same level as major life sciences hubs, it has plenty to offer and room to grow, according to ...

In this episode of Denatured, BioSpace's Head of Insights Lori Ellis and Miruna Sasu, CEO of COTA, discuss the challenges of ...

Legend Biotech is building a new $150 million manufacturing plant, with its partner Johnson & Johnson, with the goal of ...

As per the Thursday release, Endo will be folded into Mallinckrodt, which will then continue as the holding entity for the ...

With what analysts are calling "strong" data, Amgen plans to file a regulatory submission for Uplizna, currently approved for ...

Johnson & Johnson has been fighting thousands of lawsuits over its now-discontinued talc products for 16 years. A pending ...

According to Judge Kenneth Bell, there is a lack of evidence to conclude that Merck willingly misrepresented the safety of ...

Gilead plans to go straight to Phase III studies for once-yearly lenacapavir, while GSK and Viiv will push forward with their ...

Facing declining valuations and funding challenges, public biotechs like bluebird bio are going private to restructure, ...

Ionis will receive $280 million upfront and could get up to $660 million in future milestone payments. Ono will take charge ...